Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Seasonique

Roche's Perjeta pertuzumab

Daily Brief: Biosimilar Herceptin can’t make Perjeta cost effective and more

E-cigarettes can save lives - Teva gains approval for EpiPen generic

- PMLiVE

Regeneron and Teva close gap on rivals with NGF pain drug

Fasinumab was associated with less pain and improved functional ability compared to placebo

- PMLiVE

First migraine prevention drug to hit European market

European Commission green lights Novartis’ Aimovig

- PMLiVE

Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

Three new biosimilars also gets the green light

EU flag

UK pharma cheers EU science announcement

UK won't be excluded from Horizon research collaboration

- PMLiVE

Europe’s public-private alliance targets pain management

Innovative Medicines Initiative (IMI) brings pharma together with academia and patient groups in underserved area

- PMLiVE

Pharma sees European generics export plan as anti-innovation

EFPIA condemns plans - but European Commission says changes would create jobs in Europe

- PMLiVE

EMA set to review Teva’s migraine injection

Fremanezumab could be approved for prophylactic use of migraines

AstraZeneca AZ

AZ gets EMA green light for severe asthma drug Fasenra

The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero

- PMLiVE

Teva cuts 25% of workforce, with Israel taking a heavy toll

But share prices increase by almost 14%

- PMLiVE

Teva sheds R&D chief after new CEO takes the helm

Kåre Schultz begins remoulding the Israeli pharma firm

- PMLiVE

EU’s first health report card – must do better

Report implies Europe must shift its focus to disease prevention

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links